原发T790M突变非小细胞肺癌研究进展
随着检测技术的发展,原发T790M突变检出率不断增加,三代表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)出现为其提供治疗机会.临床常重视继发T790M突变,而对原发T790M突变忽视或关注度不够.本综述发现原发T790M突变发生率波动大,主要受检测技术影响.原发T790M突变丰度多较低,易合并其他基因改变,是不良的预测和预后指标,一代和二代EGFR-TKIs疗效欠佳,奥希替尼的治疗价值有待研究....
Gespeichert in:
| Veröffentlicht in: | Zhongguo fei ai za zhi 2019-05, Vol.22 (5), p.324-328 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 5 |
| container_start_page | 324 |
| container_title | Zhongguo fei ai za zhi |
| container_volume | 22 |
| creator | 王鑫 钟殿胜 |
| description | 随着检测技术的发展,原发T790M突变检出率不断增加,三代表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)出现为其提供治疗机会.临床常重视继发T790M突变,而对原发T790M突变忽视或关注度不够.本综述发现原发T790M突变发生率波动大,主要受检测技术影响.原发T790M突变丰度多较低,易合并其他基因改变,是不良的预测和预后指标,一代和二代EGFR-TKIs疗效欠佳,奥希替尼的治疗价值有待研究. |
| doi_str_mv | 10.3779/j.issn.1009-3419.2019.05.10 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7665962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>zgfazz201905010</wanfj_id><sourcerecordid>zgfazz201905010</sourcerecordid><originalsourceid>FETCH-LOGICAL-p870-db4141afbf7bcd43e35a93b429f0a4e8248bc3174f2e3cbfc6e77a00900498033</originalsourceid><addsrcrecordid>eNpVkM1Kw0AUhQdRbK0-hQtXSe9kJpnMRpDiH1TcdD_MpDMxpU1DYhW7U8GVWAQFRaxudaUbF7rwaULqWxipLtzccznn8nG4CC1jsAljvN6xoyyLbQzALUIxtx0oB7ilM4OqmHNuedhns-X-d1JBC1nWAfAcTug8qhCMgVNKqqieXzzko8sW47BTPB_no5uv-3H-Mio-zian48nJe3F7XjxeFU9vk8-7_PV6Ec0Z2c300q_WUGtjvdXYspq7m9uNtaaV-AystqKYYmmUYSpoU6KJKzlR1OEGJNW-Q30VEMyocTQJlAk8zZgs2wJQ7gMhNbQ6xSYD1dPtQMf7qeyKJI16Mj0SfRmJ_0kc7YmwfyCY57ncc0rAyhRwKGMj41B0-oM0LhuLYWjkcPjzM3ABA_kGxFxvpQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>原发T790M突变非小细胞肺癌研究进展</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>王鑫 ; 钟殿胜</creator><creatorcontrib>王鑫 ; 钟殿胜</creatorcontrib><description>随着检测技术的发展,原发T790M突变检出率不断增加,三代表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)出现为其提供治疗机会.临床常重视继发T790M突变,而对原发T790M突变忽视或关注度不够.本综述发现原发T790M突变发生率波动大,主要受检测技术影响.原发T790M突变丰度多较低,易合并其他基因改变,是不良的预测和预后指标,一代和二代EGFR-TKIs疗效欠佳,奥希替尼的治疗价值有待研究.</description><identifier>ISSN: 1009-3419</identifier><identifier>EISSN: 1999-6187</identifier><identifier>DOI: 10.3779/j.issn.1009-3419.2019.05.10</identifier><identifier>PMID: 31109443</identifier><language>chi ; eng</language><publisher>天津市和平区南京路228号300020: 天津医科大学总医院肿瘤内科,天津,300052</publisher><subject>Mini-Review ; 综述</subject><ispartof>Zhongguo fei ai za zhi, 2019-05, Vol.22 (5), p.324-328</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>版权所有©《中国肺癌杂志》编辑部2019 Copyright ©2019 Chinese Journal of Lung Cancer. All rights reserved. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/zgfazz/zgfazz.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665962/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665962/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>王鑫</creatorcontrib><creatorcontrib>钟殿胜</creatorcontrib><title>原发T790M突变非小细胞肺癌研究进展</title><title>Zhongguo fei ai za zhi</title><description>随着检测技术的发展,原发T790M突变检出率不断增加,三代表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)出现为其提供治疗机会.临床常重视继发T790M突变,而对原发T790M突变忽视或关注度不够.本综述发现原发T790M突变发生率波动大,主要受检测技术影响.原发T790M突变丰度多较低,易合并其他基因改变,是不良的预测和预后指标,一代和二代EGFR-TKIs疗效欠佳,奥希替尼的治疗价值有待研究.</description><subject>Mini-Review</subject><subject>综述</subject><issn>1009-3419</issn><issn>1999-6187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkM1Kw0AUhQdRbK0-hQtXSe9kJpnMRpDiH1TcdD_MpDMxpU1DYhW7U8GVWAQFRaxudaUbF7rwaULqWxipLtzccznn8nG4CC1jsAljvN6xoyyLbQzALUIxtx0oB7ilM4OqmHNuedhns-X-d1JBC1nWAfAcTug8qhCMgVNKqqieXzzko8sW47BTPB_no5uv-3H-Mio-zian48nJe3F7XjxeFU9vk8-7_PV6Ec0Z2c300q_WUGtjvdXYspq7m9uNtaaV-AystqKYYmmUYSpoU6KJKzlR1OEGJNW-Q30VEMyocTQJlAk8zZgs2wJQ7gMhNbQ6xSYD1dPtQMf7qeyKJI16Mj0SfRmJ_0kc7YmwfyCY57ncc0rAyhRwKGMj41B0-oM0LhuLYWjkcPjzM3ABA_kGxFxvpQ</recordid><startdate>20190520</startdate><enddate>20190520</enddate><creator>王鑫</creator><creator>钟殿胜</creator><general>天津医科大学总医院肿瘤内科,天津,300052</general><general>中国肺癌杂志编辑部</general><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20190520</creationdate><title>原发T790M突变非小细胞肺癌研究进展</title><author>王鑫 ; 钟殿胜</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p870-db4141afbf7bcd43e35a93b429f0a4e8248bc3174f2e3cbfc6e77a00900498033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi ; eng</language><creationdate>2019</creationdate><topic>Mini-Review</topic><topic>综述</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>王鑫</creatorcontrib><creatorcontrib>钟殿胜</creatorcontrib><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Zhongguo fei ai za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>王鑫</au><au>钟殿胜</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>原发T790M突变非小细胞肺癌研究进展</atitle><jtitle>Zhongguo fei ai za zhi</jtitle><date>2019-05-20</date><risdate>2019</risdate><volume>22</volume><issue>5</issue><spage>324</spage><epage>328</epage><pages>324-328</pages><issn>1009-3419</issn><eissn>1999-6187</eissn><abstract>随着检测技术的发展,原发T790M突变检出率不断增加,三代表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)出现为其提供治疗机会.临床常重视继发T790M突变,而对原发T790M突变忽视或关注度不够.本综述发现原发T790M突变发生率波动大,主要受检测技术影响.原发T790M突变丰度多较低,易合并其他基因改变,是不良的预测和预后指标,一代和二代EGFR-TKIs疗效欠佳,奥希替尼的治疗价值有待研究.</abstract><cop>天津市和平区南京路228号300020</cop><pub>天津医科大学总医院肿瘤内科,天津,300052</pub><pmid>31109443</pmid><doi>10.3779/j.issn.1009-3419.2019.05.10</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1009-3419 |
| ispartof | Zhongguo fei ai za zhi, 2019-05, Vol.22 (5), p.324-328 |
| issn | 1009-3419 1999-6187 |
| language | chi ; eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7665962 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Mini-Review 综述 |
| title | 原发T790M突变非小细胞肺癌研究进展 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%E5%8E%9F%E5%8F%91T790M%E7%AA%81%E5%8F%98%E9%9D%9E%E5%B0%8F%E7%BB%86%E8%83%9E%E8%82%BA%E7%99%8C%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95&rft.jtitle=Zhongguo%20fei%20ai%20za%20zhi&rft.au=%E7%8E%8B%E9%91%AB&rft.date=2019-05-20&rft.volume=22&rft.issue=5&rft.spage=324&rft.epage=328&rft.pages=324-328&rft.issn=1009-3419&rft.eissn=1999-6187&rft_id=info:doi/10.3779/j.issn.1009-3419.2019.05.10&rft_dat=%3Cwanfang_jour_pubme%3Ezgfazz201905010%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31109443&rft_wanfj_id=zgfazz201905010&rfr_iscdi=true |